Loading stock data…
Madrigal Pharmaceuticals (MDGL)
$527.28+14.63 (+2.85%)
Market ClosedLast close Jun 29
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Madrigal Pharmaceuticals, Inc. in the Healthcare sector is trading at $527.28 with a market capitalization of $11.6B. Wall Street consensus targets $678.71 (14 analysts), implying a +28.7% move over the next 12 months. The stock is currently 14% below its 52-week high of $615.00, remaining 6.4% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +28.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $311.34M↓ | $321.08M↑ | $287.27M↑ | $212.80M↑ | $137.25M |
| Gross Profit | $284.49M↓ | $296.63M↑ | $269.15M↑ | $203.74M↑ | $132.74M |
| Operating Income | -$92.72M↓ | -$59.61M↑ | -$113.97M↓ | -$47.20M↑ | -$79.31M |
| Net Income | -$94.39M↓ | -$58.58M↑ | -$114.19M↓ | -$42.28M↑ | -$73.24M |
Peer Comparison
JNJUNHPFE
Fundamentals
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor bet...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$11.55B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-56.94%
Volume
Today's trading volume
446,029
Recent News
3 late-stage MASH drugs that could rival Rezdiffra
The red-hot market has plenty of room for additional therapies from big name players and clinical stage companies alike.
3 Under-the-Radar Stocks to Buy and Hold for a Decade
All three could become highly prominent biotech companies within 10 years.
The Bull Case For Madrigal Pharmaceuticals (MDGL) Could Change Following New Rezdiffra Cardiometabolic Data Release
In late May 2026, Madrigal Pharmaceuticals reported new Phase 3 and real-world data at the EASL Congress showing Rezdiffra reduced multiple markers of cardiovascular and liver-related risk in MASH patients, including improvements in atherogenic lipids and liver stiffness. An especially important finding was that Rezdiffra’s lipid and liver-risk benefits appeared consistent regardless of baseline statin use, suggesting potential utility across a broad range of cardiometabolic profiles in...
Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?
Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Madrigal (MDGL) Data Highlights Rezdiffra’s Cardiometabolic Benefits for MASH Patients at EASL Congress
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the best high short interest stocks with highest upside potential. On May 27, Madrigal presented new data at the 2026 EASL Congress, reinforcing Rezdiffra as a foundational therapy for metabolic dysfunction-associated steatohepatitis/MASH. Secondary analyses from the Phase 3 MAESTRO program demonstrated that the medication improved atherogenic lipid profiles, […]